Loading...

Novo Nordisk A/S

NVOā€¢NYSE
Healthcare
Biotechnology
$44.28
$-0.46(-1.03%)
U.S. Market opens in 3h 43m

Novo Nordisk A/S (NVO) Stock Overview

Explore Novo Nordisk A/Sā€™s financial performance, market position, analyst ratings, and future outlook.

Meyka AI Score

Z

Key Financials

Market Cap196.6B
P/E Ratio10.32
EPS (TTM)$4.30
ROE0.66%
Fundamental Analysis

AI Price Forecasts

1 Month$33.15
3 Months$56.35
1 Year Target$0.00

NVO Stock Analysis & Investment Overview

Our comprehensive AI-powered analysis of Novo Nordisk A/S (NVO) provides investors with deep insights into the stock's performance, growth potential, and market positioning. With a Meyka AI Score of B+, this stock demonstrates moderate investment characteristics based on our advanced machine learning models.

The current technical analysis reveals key indicators including an RSI of 56.59, suggesting the stock is in a neutral condition. Our forecasting models predict significant price movements, with a 12-month target of $0.00.

Key financial metrics showcase the company's fundamental strength, including a P/E ratio of 10.32 and a market capitalization of 196.6B. These metrics, combined with our AI analysis, provide a comprehensive view for both institutional and retail investors.

1-Day Change
-1.10%
5-Day Change
-5.99%
1-Month Change
9.21%
3-Month Change
-10.12%
6-Month Change
-6.94%
Year-to-Date (YTD) Change
-13.03%
1-Year Change
-33.97%
3-Year Change
-47.50%
5-Year Change
11.13%
All-Time (Max) Change
27556.25%

Contact Information

https://www.novonordisk.com
45 44 44 88 88
Novo Alle 1, Bagsvaerd, NaN, 2880

Company Facts

77,406 Employees
IPO DateApr 30, 1981
CountryDK
Actively Trading

Frequently Asked Questions